CoreCap Advisors LLC Has $224,000 Stake in Gilead Sciences, Inc. $GILD

CoreCap Advisors LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 72.4% during the third quarter, Holdings Channel.com reports. The firm owned 2,015 shares of the biopharmaceutical company’s stock after selling 5,286 shares during the period. CoreCap Advisors LLC’s holdings in Gilead Sciences were worth $224,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. GoalVest Advisory LLC lifted its stake in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $27,000. Putney Financial Group LLC grew its position in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the period. Howard Hughes Medical Institute bought a new position in Gilead Sciences during the second quarter valued at $30,000. Finally, Kilter Group LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth $33,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on GILD shares. Scotiabank initiated coverage on shares of Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price on the stock. Morgan Stanley raised their price target on Gilead Sciences from $147.00 to $151.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. Daiwa Capital Markets increased their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Finally, Truist Financial assumed coverage on Gilead Sciences in a research report on Monday, November 24th. They set a “buy” rating and a $140.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.20.

Gilead Sciences Stock Performance

Shares of GILD opened at $122.60 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $89.02 and a 52 week high of $128.70. The stock has a market cap of $152.11 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 0.64 and a beta of 0.33. The business has a 50-day simple moving average of $123.28 and a two-hundred day simple moving average of $117.77. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period in the prior year, the business posted $2.02 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This represents a 20.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 136,257 shares of company stock valued at $16,855,192 in the last quarter. Company insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.